ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants

Autor: Jeffrey Seow, Carl Graham, Sadie R. Hallett, Thomas Lechmere, Thomas J.A. Maguire, Isabella Huettner, Daniel Cox, Hataf Khan, Suzanne Pickering, Rebekah Roberts, Anele Waters, Christopher C. Ward, Christine Mant, Michael J. Pitcher, Jo Spencer, Julie Fox, Michael H. Malim, Katie J. Doores
Rok vydání: 2021
Předmět:
Zdroj: Cell reports. 39(5)
ISSN: 2211-1247
Popis: Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response.
Databáze: OpenAIRE